Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights

Biogen Idec Inc. rose to its highest value ever after the drugmaker agreed to buy partner Elan Corp.’s stake in the Tysabri multiple sclerosis medicine for $3.25 billion in cash plus future royalties.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.